| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.9 |